- Product
- Boots, withdraws from the pharmacy market in 3 years
- by Kim JiEun Apr 8, 2020 06:21am
- 'Boots', which opened ambitiously in Korea, claiming to be a premium health & beauty store, eventually withdrew their business after failing to overcome the continuing sluggish profitability. According to the industry on the 6th, the company recently decided to withdraw its entire business and closed the recently opened stores. In 2017,
- Product
- President Moon posted a memorial message on SNS
- by Kang, Shin-Kook Apr 7, 2020 06:40am
- On the 4th, President Moon Jae-in expressed his condolences to Ms. A, a medical doctor working in Gyeongsan, Gyeongbuk, infected with COVID-19. President Moon said through social networking services (SNS), "It was very sad that our infected medical staff was sacrificed for the first time while treating a COVID-19 infected patient." Mr.
- Product
- Does Tylenol prevent COVID-19 infection?
- by Kim JiEun Apr 3, 2020 06:34am
- Tylenol stockpiles are showing signs of prolongation which were initiated by the World Health Organization (WHO) According to pharmacies on the 1st, there are more customers who want to buy Tylenol, and many of them want to buy in bulk. Tylenol's full-scale hoarding began after WHO recently advised patients with suspicion of COVID-19 to
- Product
- 7 out of 10 doctors, the government was wrong with COVID-19
- by Kang, Shin-Kook Apr 1, 2020 06:17am
- Seven out of ten doctors found that the government's response to the COVID-19 was wrong. The Korean Medical Association (Chairman Dae-Zip Choi) conducted a questionnaire survey on the COVID-19 events through the doctoral survey on the 20th to 24th, and published the results on the 30th. As a result of the survey, 39.1% (621 people) of the
- Product
- Korea’s first epidemiological report on COVID-19 deaths
- by Lee, in-bok Mar 31, 2020 06:29am
- A study analyzed deaths from COVID-19 in Korea and found male patients in 70s with chronic cardiac disorder like hypertension were critically affected. Apparently, most of them had died in average 10 days after the onset COVID-19 symptoms, and their average time to death was unaffected regardless of underlying illness. First epidemio
- Product
- Who will succeed in COVID-19 treatment?
- by choi-sun Mar 25, 2020 06:01am
- As pharmaceutical companies around the world are plunging into the development of vaccines and treatments for COVID-19 treatment, attention is focused on who will succeed in commercialization. Among the treatments, Gilead Sciences entered Phase III of clinical trials, and in the field of vaccines, it entered Phase I by Moderna Therapeutics. H
- Product
- CartiLife has passed 5 years follow-up result
- by choi. sun Mar 11, 2020 06:27am
- Domestic osteoarthritic treatment has shown positive results for bone repair in the long-term follow-up of five years. The results are encouraging, as the osteoarthritis treatments that have shown their intention to compete have failed to demonstrate 'Disease Modifying OestoArthritis Drugs' (DMOAD) that structurally inhibit disease progressio
- Product
- Panic buying Tylenol-Advil in fear of COVID-19 fake news
- by Jung, Heung-Jun Mar 4, 2020 06:27am
- Tylenol and Advil are out of stock as their demands have skyrocketed due to online fake news encouraging panic buying of OTC drugs and claiming the Korean government’s containment of COVID-19 has failed. On Mar. 2, a multiple online pharmacies have posted notice on shortage of Tylenol, Advil and Aspirin. Apparently, the circulating
- Product
- What drug will be replaced by Belviq’s withdrawal?
- by Lee, in-bok Feb 18, 2020 10:49am
- As Ildong’s Belviq, which dominated the obese drug market for a long time, is finally exiting the market, there is a growing interest in which drug will fill this gap. Obesity experts are predicting that safety-oriented prescriptions may be available for the time being, while Saxenda and Qsymia are expected to benefit directly. The Min
- Product
- Ebola drug Remdesivir is used to treat COVID-19
- by Lee, In-Bok Feb 13, 2020 06:28am
- Remdesivir by Gilead, which is being developed as an Ebola treatment, is expected to benefit significantly from the spread of COVID-19. The explosive demand for therapeutics around the world has led to unintended recruitment of clinical trials, which has resulted in significant time and cost savings. In some cases, the possibility of quick pe
